Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses

Journal of Immunology

Volumn 193, Issue 2, 2014, Pages 961-969

  Macho Fernandez, Elodie ^a,b,c,d,e   Cruz, Luis Javier ^f   Ghinnagow, Reem ^a,b,c,d,e   Fontaine, Josette ^a,b,c,d,e   Bialecki, Emilie ^a,b,c,d,e   Frisch, Benoit ^g   Trottein, François ^a,b,c,d,e   Faveeuw, Christelle ^a,b,c,d,e  

^a INSERM U1019   (France)

^b UNIV LILLE   (France)

^c CNRS   (France)

^d INSERM   (France)

^e Institut Federatif de Recherche 142   (France)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD8ALPHA ANTIGEN; DEC205 RECEPTOR; LECTIN RECEPTOR; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; ENCAPSULATION; LUNG METASTASIS; MALE; MELANOMA B16; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES; ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; GALACTOSYLCERAMIDES; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NANOPARTICLES; NATURAL KILLER T-CELLS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN;

EID: 84904246019     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1303029     Document Type: Article

References (55)

1. Andersen, B. M., and J. R. Ohlfest. 2012. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett. 325: 155-164.
2. Dougan, M., and G. Dranoff. 2009. Immune therapy for cancer. Annu. Rev. Immunol. 27: 83-117.
3. Cerundolo, V., J. D. Silk, S. H. Masri, and M. Salio. 2009. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol. 9: 28-38.
4. Dhodapkar, M. V., and J. Richter. 2011. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin. Immunol. 140: 160-166.
5. Pilones, K. A., J. Aryankalayil, and S. Demaria. 2012. Invariant NKT cells as novel targets for immunotherapy in solid tumors. Clin. Dev. Immunol. 2012: 720803.
6. Motohashi, S., and T. Nakayama. 2009. Invariant natural killer T cell-based immunotherapy for cancer. Immunotherapy 1: 73-82.
7. Schneiders, F. L., R. J. Scheper, B. M. vonBlomberg, A.M. Woltman, H. L. Janssen, A. J. van den Eertwegh, H. M. Verheul, T. D. de Gruijl, and H. J. van der Vliet. 2011. Clinical experience with a-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin. Immunol. 140: 130-141.
8. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
9. Terabe, M., and J. A. Berzofsky. 2007. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 28: 491-496.
10. Fujii, S., S. Motohashi, K. Shimizu, T. Nakayama, Y. Yoshiga, and M. Taniguchi. 2010. Adjuvant activity mediated by iNKT cells. Semin. Immunol. 22: 97-102.
11. Kobayashi, E., K. Motoki, T. Uchida, H. Fukushima, and Y. Koezuka. 1995. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7: 529-534.
12. Nakagawa, R., K. Motoki, H. Nakamura, H. Ueno, R. Iijima, A. Yamauchi, S. Tsuyuki, T. Inamoto, and Y. Koezuka. 1998. Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol. Res. 10: 561-568.
13. Giaccone, G., C. J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. von Blomberg, R. J. Scheper, H. J. van der Vliet, A. J. van den Eertwegh, et al. 2002. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8: 3702-3709.
14. Molling, J. W., W. Kölgen, H. J. van der Vliet, M. F. Boomsma, H. Kruizenga, C. H. Smorenburg, B. G. Molenkamp, J. A. Langendijk, C. R. Leemans, B. M. von Blomberg, et al. 2005. Peripheral blood IFN-gamma-secreting Valpha24+ Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 116: 87-93.
15. Parekh, V. V., M. T. Wilson, D. Olivares-Villagómez, A. K. Singh, L. Wu, C. R. Wang, S. Joyce, and L. Van Kaer. 2005. Glycolipid antigen induces longterm natural killer T cell anergy in mice. J. Clin. Invest. 115: 2572-2583.
16. Faveeuw, C., and F. Trottein. 2014. Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines. Cancer Res. 74: 1632-1638.
17. Bezbradica, J. S., A. K. Stanic, N. Matsuki, H. Bour-Jordan, J. A. Bluestone, J. W. Thomas, D. Unutmaz, L. Van Kaer, and S. Joyce. 2005. Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J. Immunol. 174: 4696-4705.
18. Fujii, S., K. Shimizu, M. Kronenberg, and R. M. Steinman. 2002. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3: 867-874.
19. Iyoda, T., M. Ushida, Y. Kimura, K. Minamino, A. Hayuka, S. Yokohata, H. Ehara, and K. Inaba. 2010. Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation. Int. Immunol. 22: 905-913.
20. Chang, D. H., K. Osman, J. Connolly, A. Kukreja, J. Krasovsky, M. Pack, A. Hutchinson, M. Geller, N. Liu, R. Annable, et al. 2005. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201: 1503-1517.
21. Nieda, M., M. Okai, A. Tazbirkova, H. Lin, A. Yamaura, K. Ide, R. Abraham, T. Juji, D. J. Macfarlane, and A. J. Nicol. 2004. Therapeutic activation of Valpha24+ Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389.
22. Shimizu, K., M. Asakura, J. Shinga, Y. Sato, S. Kitahara, K. Hoshino, T. Kaisho, S. P. Schoenberger, T. Ezaki, and S. Fujii. 2013. Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J. Immunol. 190: 5609-5619.
23. Shimizu, K., Y. Kurosawa, M. Taniguchi, R. M. Steinman, and S. Fujii. 2007. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J. Exp. Med. 204: 2641-2653.
24. Shortman, K., and W. R. Heath. 2010. The CD8+ dendritic cell subset. Immunol. Rev. 234: 18-31.
25. Arora, P., A. Baena, K. O. Yu, N. K. Saini, S. S. Kharkwal, M. F. Goldberg, S. Kunnath-Velayudhan, L. J. Carreño, M. M. Venkataswamy, J. Kim, et al. 2014. A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 40: 105-116.
26. Farrand, K. J., N. Dickgreber, P. Stoitzner, F. Ronchese, T. R. Petersen, and I. F. Hermans. 2009. Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens. J. Immunol. 183: 7732-7742.
27. Schmieg, J., G. Yang, R. W. Franck, N. Van Rooijen, and M. Tsuji. 2005. Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl. Acad. Sci. USA 102: 1127-1132.
28. Jung, S., D. Unutmaz, P. Wong, G. Sano, K. De los Santos, T. Sparwasser, S. Wu, S. Vuthoori, K. Ko, F. Zavala, et al. 2002. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17: 211-220.
29. Mendiratta, S. K., W. D. Martin, S. Hong, A. Boesteanu, S. Joyce, and L. Van Kaer. 1997. CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6: 469-477.
30. Macho Fernandez, E., J. Chang, J. Fontaine, E. Bialecki, F. Rodriguez, E. Werkmeister, V. Krieger, C. Ehret, B. Heurtault, S. Fournel, et al. 2012. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles. Int. J. Pharm. 423: 45-54.
31. Cruz, L. J., P. J. Tacken, R. Fokkink, B. Joosten, M. C. Stuart, F. Albericio, R. Torensma, and C. G. Figdor. 2010. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release 144: 118-126.
32. Chang, W. S., J. Y. Kim, Y. J. Kim, Y. S. Kim, J. M. Lee, M. Azuma, H. Yagita, and C. Y. Kang. 2008. Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J. Immunol. 181: 6707-6710.
33. Parekh, V. V., S. Lalani, S. Kim, R. Halder, M. Azuma, H. Yagita, V. Kumar, L.Wu, and L. V. Kaer. 2009. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J. Immunol. 182: 2816-2826.
34. Idoyaga, J., N. Suda, K. Suda, C. G. Park, and R. M. Steinman. 2009. Antibody to Langerin/CD207 localizes large numbers of CD8alpha+ dendritic cells to the marginal zone of mouse spleen. Proc. Natl. Acad. Sci. USA 106: 1524-1529.
35. Bonifaz, L. C., D. P. Bonnyay, A. Charalambous, D. I. Darguste, S. Fujii, H. Soares, M. K. Brimnes, B. Moltedo, T. M. Moran, and R. M. Steinman. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199: 815-824.
36. Idoyaga, J., A. Lubkin, C. Fiorese, M. H. Lahoud, I. Caminschi, Y. Huang, A. Rodriguez, B. E. Clausen, C. G. Park, C. Trumpfheller, and R. M. Steinman. 2011. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc. Natl. Acad. Sci. USA 108: 2384-2389.
37. Birkholz, K., M. Schwenkert, C. Kellner, S. Gross, G. Fey, B. Schuler-Thurner, G. Schuler, N. Schaft, and J. Dörrie. 2010. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. Blood 116: 2277-2285.
38. Berzins, S. P., M. J. Smyth, and A. G. Baxter. 2011. Presumed guilty: natural killer T cell defects and human disease. Nat. Rev. Immunol. 11: 131-142.
39. Barral, P., M. D. Sánchez-Niño, N. van Rooijen, V. Cerundolo, and F. D. Batista. 2012. The location of splenic NKT cells favours their rapid activation by bloodborne antigen. EMBO J. 31: 2378-2390.
40. Ishii, M., and N. Kojima. 2013. Effective stimulation of invariant natural killer T cells by oligomannose-coated liposomes. Int. Immunopharmacol. 15: 685-692.
41. McKee, S. J., V. L. Young, F. Clow, C. M. Hayman, M. A. Baird, I. F. Hermans, S. L. Young, and V. K. Ward. 2012. Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses. J. Control. Release 159: 338-345.
42. Kawasaki, N., J. L. Vela, C. M. Nycholat, C. Rademacher, A. Khurana, N. van Rooijen, P. R. Crocker, M. Kronenberg, and J. C. Paulson. 2013. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation. Proc. Natl. Acad. Sci. USA 110: 7826-7831.
43. Bai, L., M. G. Constantinides, S. Y. Thomas, R. Reboulet, F. Meng, F. Koentgen, L. Teyton, P. B. Savage, and A. Bendelac. 2012. Distinct APCs explain the cytokine bias of α-galactosylceramide variants in vivo. J. Immunol. 188: 3053-3061.
44. King, I. L., E. Amiel, M. Tighe, K. Mohrs, N. Veerapen, G. Besra, M. Mohrs, and E. A. Leadbetter. 2013. The mechanism of splenic invariant NKT cell activation dictates localization in vivo. J. Immunol. 191: 572-582.
45. Bialecki, E., E. Macho Fernandez, S. Ivanov, C. Paget, J. Fontaine, F. Rodriguez, L. Lebeau, C. Ehret, B. Frisch, F. Trottein, and C. Faveeuw. 2011. Spleen-resident CD4+ and CD4- CD8α- dendritic cell subsets differ in their ability to prime invariant natural killer T lymphocytes. PLoS ONE 6: e26919.
46. Simkins, H. M., E. Hyde, K. J. Farrand, M. L. Ong, M. A. Degli-Esposti, I. F. Hermans, and F. Ronchese. 2011. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo. J. Leukoc. Biol. 89: 753-762.
47. Edelson, B. T., T. R. Bradstreet, K. Hildner, J. A. Carrero, K. E. Frederick, W. Kc, R. Belizaire, T. Aoshi, R. D. Schreiber, M. J. Miller, et al. 2011. CD8α(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. Immunity 35: 236-248.
48. Barral, D. C., and M. B. Brenner. 2007. CD1 antigen presentation: how it works. Nat. Rev. Immunol. 7: 929-941.
49. Mashayekhi, M., M. M. Sandau, I. R. Dunay, E. M. Frickel, A. Khan, R. S. Goldszmid, A. Sher, H. L. Ploegh, T. L. Murphy, L. D. Sibley, and K. M. Murphy. 2011. CD8α(+) dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites. Immunity 35: 249-259.
50. Bal, S. M., S. Hortensius, Z. Ding, W. Jiskoot, and J. A. Bouwstra. 2011. Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination. Vaccine 29: 1045-1052.
51. Schlosser, E., M. Mueller, S. Fischer, S. Basta, D. H. Busch, B. Gander, and M. Groettrup. 2008. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26: 1626-1637.
52. Tacken, P. J., I. S. Zeelenberg, L. J. Cruz, M. A. van Hout-Kuijer, G. van de Glind, R. G. Fokkink, A. J. Lambeck, and C. G. Figdor. 2011. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 118: 6836-6844.
53. Semmling, V., V. Lukacs-Kornek, C. A. Thaiss, T. Quast, K. Hochheiser, U. Panzer, J. Rossjohn, P. Perlmutter, J. Cao, D. I. Godfrey, et al. 2010. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat. Immunol. 11: 313-320.
54. Bai, L., S. Deng, R. Reboulet, R. Mathew, L. Teyton, P. B. Savage, and A. Bendelac. 2013. Natural killer T (NKT)-B-cell interactions promote prolonged antibody responses and long-term memory to pneumococcal capsular polysaccharides. Proc. Natl. Acad. Sci. USA 110: 16097-16102.
55. Mattarollo, S. R., K. Steegh, M. Li, H. Duret, S. Foong Ngiow, and M. J. Smyth. 2013. Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol. Cell Biol. 91: 105-114.